Table 2: List of ongoing clinical trials in androgen indifferent prostate cancer.
Clinical trials enrolling patients with androgen indifferent prostate cancer. This includes clinical trials enrolling patients with “neuroendocrine prostate cancer,” “small cell prostate cancer,” “aggressive variant prostate carcinoma,” “double-negative prostate cancer,” or “extrapulmonary small cell carcinoma” whose status was listed as “Not yet recruiting,” “Recruiting,” or “Active, not recruiting” on clinicaltrials.gov as of 10/27/20.
| NCT# | Title | Phase | AIPC Variant Included | Status |
|---|---|---|---|---|
| NCT03179410 | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC) | Phase 2 | NEPC | Active, not recruiting |
| NCT03263650 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC (C-COLA) | Phase 2 | AVPC | Active, not recruiting |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Phase 2 | NEPC | Recruiting |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | Phase 1 | NEPC | Recruiting |
| NCT03896503 | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | Phase 2 | Extrapulmonary SCC | Recruiting |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC | Phase 1/2 | NEPC | Recruiting |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | Phase 2 | DNPC | Recruiting |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Phase 1 | AVPC/NEPC | Recruiting |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Phase 2 | AVPC | Not yet recruiting |
| NCT02893917 | Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | NEPC | Active, not recruiting |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | NEPC | Recruiting |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Phase 2 | NEPC | Recruiting |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Phase1/2 | Extrapulmonary SCC | Recruiting |
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | Phase 1/2 | Extrapulmonary SCC | Recruiting |
| NCT03837977 | Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NET02) | Phase 2 | Extrapulmonary Poorly Differentiated Neuroendocrine Carcinoma | Recruiting |
Abbreviations: AIPC, androgen indifferent prostate cancer; NEPC, neuroendocrine prostate cancer; AVPC, aggressive variant prostate cancer; mCRPC, metastatic castrate resistant prostate cancer; SCC, small cell carcinoma; DNPC, double negative prostate cancer